OUR LEADERSHIP TEAM
Scientific Advisory Board
Ru Chih Huang, PhD.
Chief Scientific Advisor
Ru Chih Huang, PhD, is a co-founder and Chief Scientific Advisor at Erimos Pharmaceuticals. She is the lead inventor of Erimos’ technology. Dr. Huang is currently a professor in the Department of Biology at The Johns Hopkins University. Dr. Huang’s scientific publications, addressing the function of chromosomal proteins, messenger RNA, and RNA polymerases, represent the major aspect of her earlier contributions to the field of molecular biology. Her more recent research focuses on the understanding of viral gene transcription, replications, and oncogenic development in humans. The discoveries of mutation-insensitive antiviral and anticancer compounds, the derivatives of plant lignan NDGA, have led to a series of recent patents and publications.
Dr. Huang obtained a BS degree at National Taiwan University, a PhD at Ohio State University, and conducted postdoctoral research at the California Institute of Technology. She has served as a member of the Board of Scientific Counselors to a variety of private and governmental agencies including the Wistar Institute, the Institute of Molecular and Cell Biology, the University of Singapore, Cetus Corporation, the National Cancer Institute, and the National Institute on Aging, National Institutes of Health. Dr. Huang was one of the founding directors of the Institute of Molecular Biology in Taiwan. She is a member of Academia Sinica and continues to be a scientific board member of several institutes at Academia Sinica, Taiwan.
Daniel D. Von Hoff, MD, FACP
Dr, Von Hoff is currently Physician in Chief, Senior Investigator and Director of Translational Research at the Translational Genomics Research Institute’s (TGen) Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, AZ. He also serves as Chief Scientific Officer for US Oncology and Scottsdale Clinical Research Institute.
Dr. Von Hoff was involved in the early development of many cancer drugs, including paclitaxel, docetaxel, gemcitabine and others. Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in June 2004–March 2010. He is past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (recently acquired by Genzyme). He is founder and Editor Emeritus of Investigational New Drugs—The Journal of New Anticancer Agents; and Editor-in-Chief of Molecular Cancer Therapeutics. Dr. Von Hoff has published more than 531 papers, 129 book chapters, and more than 891 abstracts.
Dr. Mohrland, was previously CEO and President of Erimos and now serves as a scientific advisor. He has extensive experience in the pharmaceutical industry building and managing global organizations focused on the development and commercialization of oncology and other therapeutic products.
Dr. Mohrland served as Executive Vice President for GMP Companies, Inc., a global company focused on the development and commercialization of pharmaceuticals and other medical products. Prior to GMP, he spent more than 21 years with Pharmacia Corporation, Pharmacia and Upjohn, Inc. and the Upjohn Company, where he held a number of executive positions, including Vice President of Scientific, Professional and Government Operations, and Vice President of Medical Operations and Scientific Affairs.
Dr. Mohrland has served on several boards, including serving as Vice Chairman of Florida’s biotechnology industry organization. He has held several academic appointments at major universities. Dr. Mohrland received his PhD in pharmacology from Washington State University, and was a Postdoctoral Fellow at the University of Iowa. He has authored numerous scientific and medical publications and been a member of several scientific and medical societies.
J. Scott Mohrland, PhD.
Chairman of the Board and CEO
Jeffrey Khoo is a co-founder of Erimos Pharmaceuticals and serves as Executive Chairman of the Board. Jeffrey has more than 30 years of multi-industry experience including life sciences, medical devices, semiconductors, investment management, and property development.
He founded 3V SourceOne Capital Pte Ltd. (Singapore), a venture capital firm based in Silicon Valley and Singapore. He is a member of the board of directors of several real estate development companies in Malaysia, Hong Kong and China.
Jeffrey was a member of Eli Lilly & Company’s Strategic Planning Team in the Medical Instrument Division. He is a graduate of the National University of Singapore with a First Class Honors Degree in Electrical Engineering. His MBA in finance was attained at the Haas School of Business, University of California, Berkeley. He is a member of the CFA Institute.
Stephan D. Glenn, PhD.
Vice President - Clinical and Regulatory Affairs
Steve Glenn has 35 years experience in the clinical development and regulatory approval process for oncology therapeutic and anti-viral products. He initially joined Erimos Pharmaceuticals as a Regulatory Affairs consultant and subsequently management of Clinical Development.
Prior to joining Erimos he held a number of senior positions directing clinical development and regulatory affairs teams conducting Phase 1, 2, and/or 3 oncology clinical trials and a Phase 3 International clinical trial of a novel HIV therapeutic. During 12 years at Coulter Corporation assembled and managed the team that developed the first effective radiolabeled monoclonal antibody 131-Iodine and 90-Yttrium anti-B1 (CD20) therapeutics for Non-Hodgkin Lymphoma. As a result of ground-breaking clinical study results, this program was spun out of Coulter Corporation as the start-up Coulter Pharmaceutical with subsequent product approval. He is also experienced negotiating with governmental regulatory agencies, FDA, Health Canada, EMA. He achieved Regulatory Affairs Certification (RAC) in 1995 and was recertified multiple times.
Dr. Glenn earned his PhD in Physiology at University of Illinois Champaign-Urbana and joined the Biochemistry research staff at University of Texas MD Anderson Hospital as an Assistant Biochemist. Dr. Glenn has directed three Phase III and numerous Phase I and II US and International corporate clinical studies and has served as a clinical and regulatory consultant to numerous clients. He has twice served on the program committee of the Regulatory Affairs Professional Society Annual Meeting. His academic research experience includes 6 years on the research staff University of Texas MD Anderson Hospital. As an Inventor he has 15 issued patents, most of these patents have been commercially licensed. He is an author of 27 scientific and medical publications and numerous abstracts.
Board Director and CFO
Alex Hung is a specialist in investment strategy planning, as well as in the financial management field. He has full knowledge of the complete set of the company’s Trade Secret regarding the manufacturing methods of Nordihydroguaiaretic Acid (NGDA), which is the principal compound of Terameprocol, and other related intellectual properties of Erimos Pharmaceutical, LLC.
Mr Hung, is a member of the Ang’s Holding Company. His background is in the real estate development and management. He joined the Ang’s Holding Company (the Parent Company of Erimos ) in 1978. He has involved in various real estate development projects in Malaysia, China and Houston, Texas, USA. He received a BA degree in Commerce from University of Toronto, Canada.